Updates are available Correction dated 2024-08-13
Click to view Correction: https://doi.org/10.1007/s10147-024-02595-z
-
Authors
Yamaguchi, Tatsuro https://orcid.org/0000-0001-8454-1995
Ikegami, Masachika
Aruga, Tomoyuki
Kanemasa, Yusuke
Horiguchi, Shin-ichiro
Kawai, Kazushige
Takao, Misato
Yamada, Takeshi
Ishida, Hideyuki
-
Funding
Funding for this research was provided by:
Japan Society for the Promotion of Science (21K07187, 18K07314, 21K16437)
- License Information
-
More Information
Article History
Received: 11 January 2024
Accepted: 14 May 2024
First Online: 25 May 2024
Change Date: 13 August 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s10147-024-02595-z
Declarations
:
: Tatsuro Yamaguchi, Masachika Ikegami, Yusuke Kanemasa, Shin-ichiro Horiguchi, Kazushige Kawai, Misato Takao, Takeshi Yamada, and Hideyuki Ishida declare that they have no competing interests in this study. Tomoyuki Aruga reported receiving honoraria for lectures from Pfizer, Chugai, Eli Lilly, Kyowa Kirin, and AstraZeneca, and research funding from Pfizer.
: Approval of the research protocol by an Institutional Reviewer Board: The present study was approved by the ethical review board at Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital (2969) and the Center for Cancer Genomics and Advanced Therapeutics (AP20211209-01N).
